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Ischemic white matter injury has been relatively little studied despite its importance to the outcome of
stroke. To aid such research a new rat model has been developed in vivo and used to assess whether
blockade of the sodium/calcium exchanger is effective in protecting central axons from ischemic injury.
Vasoconstrictive agent endothelin-1 was injected into the rat spinal cord to induce ischemia. KB-R7943
or SEA0400 was administered systemically to block the operation of the sodium/calcium exchanger.
Endothelin-1 caused profound reduction of local blood perfusion and resulted in a prompt loss of axonal
conduction. Whereas recovery of conduction following vehicle administration was only to 10.5  9% of
baseline (n ¼ 8) 4.5 h after endothelin-1 injection, recovery following KB-R7943 (30 mg/kg, i.a.)
administration was increased to 35  9% of baseline (n ¼ 6; P < 0.001). SEA0400 (30 mg/kg, i.a.) was also
protective (33.2  6% of baseline, n ¼ 4; P < 0.001). Neither drug improved conduction by diminishing
the severity of the ischemia. The protective effect of KB-R7943 persisted for at least 3 days after ischemia,
as it improved axonal conduction (76.3  11% for KB-R7943 vs. 51.0  19% for vehicle; P < 0.01) and
reduced lesion area (55.6  15% for KB-R7943 vs. 77.9  9% for vehicle; P < 0.01) at this time. In
conclusion, a new model of white matter ischemia has been introduced suitable for both structural and
functional studies in vivo. Blocking the sodium/calcium exchanger protects central axons from ischemic
injury in vivo.
 2012 Elsevier Ltd. Open access under CC BY license.1. Introduction
Ischemic stroke is a major cause of permanent, severe neuro-
logical deﬁcits (Stroke Therapy Academic Industry Roundtable,
1999; Lo et al., 2003b). Although therapies such as thrombolysis
can reduce the magnitude of the damage to CNS tissue by reducing
the severity of the insult (The National Institute of Neurological
Disorders and Stroke rt-PA Stroke Study Group, 1995), therapies
that can protect the tissue from the consequences of the insult are
very limited (See review Ginsberg, 2008). One concept for neuro-
protective therapy is that after ischemia the CNS tissue exhibits
a “penumbra” (Astrup et al., 1977), i.e. an area at the periphery of
the infarct which is recruited over time, but which is potentially
salvageable with timely intervention (Memezawa et al., 1992;
Lovblad et al., 1997; Back et al., 2004). Although it is clear that most
cases of stroke involve the white matter (Ho et al., 2005), and thatlcium exchanger.
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Y license.the damage to the white matter can be at least as important in
causing neurological deﬁcits as damage to the gray matter (See
reviews Dewar et al., 1999; Gladstone et al., 2002; Goldberg and
Ransom, 2003; Pantoni, 2006; Bakiri et al., 2009), most preclin-
ical studies have targeted the graymatter. This discrepancy is partly
because the current rodent stroke models mainly involve the gray
matter as the gray matter accounts for approximately 90% of the
rodent brain in comparison with only 40e50% of the human brain
(Zhang and Sejnowski, 2000). However, research into white matter
protection has been hampered by a relative lack of experimental
models, especially models in vivo that allow for functional exami-
nation of the axons. Here we introduce such a model in the rat
spinal cord, in which axonal function can be monitored in vivo
serially over hours, or over days. The ischemia results from the
intraspinal injection of the vasoconstrictive agent endothelin-1 (ET-
1) (Yanagisawa et al., 1988). ET-1 is an important physiological
mediator, regulating vasomotor tone and blood pressure via its
effects on the blood vessels. Produced and secreted by the endo-
thelial cells, ET-1 acts on the vascular smooth muscle cells and
triggers Ca2þ-mediated smooth muscle contraction via the ETA
receptors (For review see Masaki et al., 1999). Exogenous ET-1 has
been successfully applied to induce local cerebral ischemia in both
Fig. 1. Data showing the acute model of ET-1-induced ischemia. Axonal conduction along primary afferent axons in the dorsal columns was continuously monitored (A). ET-1
injection was performed bilaterally at multiple injection sites (A & B) to induce ischemia within the dorsal columns. Blood perfusion of the spinal cord measured at the site of
ET-1 injection, relative to baseline, is presented before and after the injection (time zero; C). Increase in the frequency of electrical stimulation from 1 Hz to 50 Hz resulted in an
increase in blood ﬂow, but this was profoundly reduced by the injection of ET-1 (2.28 nmol; arrowhead). Comparable saline injection had no similar effect. The injection of ET-1
caused a complete loss of the compound action potential (CAP) within 20 min (D), and the total blockade of conduction lasted for approximately 60 min. The amplitude eventually
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1993) and white matter (Hughes et al., 2003; Frost et al., 2006;
Sozmen et al., 2009).
One strategy for axonal protection formulated by Stys, Waxman,
Ransom and colleagues (Stys et al., 1992b, 1993; Waxman et al.,
1994), is based on the fact that axons deprived of oxygen accu-
mulate Naþwithin the axoplasm due to the electrochemical inward
gradient for Naþ and the failure of adequate extrusion by the Naþ/
Kþ ATPase (“sodium pump”) because of insufﬁcient ATP. The raised
intra-axonal Naþ concentration is believed to result in the detri-
mental inﬂux of Ca2þ via reverse operation of the axolemmal
sodium/calcium exchanger (NCX) (see below). In support of this
scheme, axonal protection has been achieved by inhibiting Naþ
entry in a number of models believed to involve energy insufﬁ-
ciency, including spinal cord injury (Agrawal and Fehlings, 1996;
Hains et al., 2004) and models of multiple sclerosis (Kapoor et al.,
2003; Lo et al., 2003a; Bechtold et al., 2004).
The NCX normally serves to export axoplasmic Ca2þ at the
expense of importing Naþ, powered by the electrochemical driving
force for Naþ entry. However, if the intracellular concentration of
Naþ rises, the axon becomes depolarized and the electrochemical
Naþ gradient is therefore diminished, so that eventually the elec-
trochemical driving force for Ca2þ entry becomes dominant and the
NCX is driven in reverse mode, importing Ca2þ into the axoplasm.
In the absence of sufﬁcient energy for Ca2þ extrusion or seques-
tering, the Ca2þ accumulates and activates degradative pathways
leading to axonal degeneration (For review see Annunziato et al.,
2004). The axonal location of the NCX has been conﬁrmed in
both rat optic nerve and the dorsal columns by immunolabeling
(Steffensen et al., 1997). Accordingly, inhibitors of the reverse-mode
operation of the NCX are effective in protecting axons from anoxia
or simulated ischemia in vitro (Stys et al., 1992b; Li et al., 2000), but
whether this strategy is effective in axonal protection following
true ischemia in vivo is not known. Here we have developed and
employed a new model of ischemia to test the efﬁcacy in axonal
protection in vivo of two selective inhibitors of reverse-mode
operation of the NCX, KB-R7943 (2-[2-[4-(4-nitrobenzyloxy)
phenyl]ethyl]isothiourea methane-sulfonate) and SEA0400 (2-[4-
[(2,5-diﬂuorophenyl)methoxy]phenoxy]-5-ethoxyaniline).
2. Experimental procedures
Two protocols have been developed, one comprising an acute,
terminal examination, allowing for more controlled studies on
model characterization and initial “screening” of protective
compounds, and the other a recovery preparation, which is clini-
cally more relevant and can be used to determine whether axonal
protection is durable. All the animal procedures conformed to the
U.K. Animals (Scientiﬁc Procedures) Act, 1986 and associated
guidelines.
2.1. Acute preparation
Adult rats (Sprague-Dawley; male; 280e350 g) were anes-
thetized (1.5e2% isoﬂurane in room air) and prepared for pro-
longed electrophysiological monitoring. Preparation included
maintenance of rectal temperature (36.5  0.5 C) using a homeo-
thermic blanket (Harvard Apparatus, UK) and continuous moni-
toring of both end-tidal carbon dioxide and breathing rate, and
arterial blood pressure via cannulation of the right internal carotidrecovered to 18.5  9% of baseline (n ¼ 5) at t ¼ 270 min. In the saline control group the am
stimulation was resumed. Representative images of axons in the ventral portion of the dorsa
tissue ﬁxed at the end of electrical recording. The saline (control) axons appear normal throu
undergoing degeneration following ET-1 injection. Data in D: mean  SD. STIM: stimulatioartery, to ensure the adequacy of anesthesia. Artiﬁcial ventilation
was introduced after the trachea was intubated and a neuromus-
cular blocking agent (gallamine triethiode; Concord Pharmaceuti-
cals Ltd, Essex, UK; 40 mg/ml) administered as a bolus via the right
internal carotid artery. Electrical stimulation (50 ms duration; DS2
stimulator, Digitimer Ltd, Hertfordshire, UK) was applied to the
spinal cord via a platinum wire stimulating cathode (prepared in
house). The cathode was implanted over the junction of the intact
T8/T9 vertebrae, and the anode (a stainless steel needle electrode)
was placed subcutaneously at the right shoulder. The evoked
compound action potentials (CAPs) conducted antidromically via
the dorsal columns were differentially recorded (Neurolog System,
Digitimer Ltd, Hertfordshire, UK) every 2 min (averaged, n ¼ 64)
from two stainless steel needle electrodes positioned at the base
(‘active’) and tip (‘indifferent’) of the tail. The stimulating voltage
was gradually increased from zero until a maximal CAPwas evoked,
and then the applied voltage was selected as 1.5 times this value
(typically 60e70 V). The recording period (six-hours) started with
stimulation at 1 Hz for 60 min, followed by stimulation at 50 Hz for
210 min, returning to 1 Hz for the ﬁnal 90 min. The stimulation at
50 Hz, which is within the physiological range for many axons
(Prochazka and Gorassini, 1998), was designed to increase the
metabolic demand of the axons. The magnitude of the CAP was
normalized and expressed as a percentage of the CAP recorded at
baseline (i.e. the average amplitude of the CAPs recorded over the
ﬁrst 30 min of stimulation, declared as 100%). Functional recovery
of the axonswas expressed as the normalizedmagnitude of the CAP
recorded at t ¼ 270 min. The CAPs obtained at each speciﬁed time
point were averaged among animals.
To induce ischemia in the dorsal columns, ET-1 (2.28 nmol;
Alexis, San Diego, CA, USA) was micro-injected bilaterally into the
spinal cord (injections made w550 mm lateral to the midline, at
depths of 200 mm, 600 mm,1000 mm and 1400 mm from the surface;
8  1 ml in total) at the junction between the T11/T12 vertebrae,
90 min after the onset of the CAP recording (deﬁned as T0). The
injection was performed using a pre-pulled glass pipette
(30e50 mm tip diameter) containing the liquid to be injected,
connected by a segment of ﬂexible cannula to a 20 ml air-ﬁlled
disposable syringe (used to apply positive pressure to the
pipette). The set of injections at each site took about 90 s, after
which a 30-s interval was allowed before the glass injection pipette
was fully withdrawn to prevent back-ﬂow of the injected solution.
The second set of injections on the contralateral side was initiated
immediately to ensure bilateral inhibition of the blood ﬂow in the
spinal cord. The total injection process took about 4 min. Such
injections of saline (controls) did not diminish themagnitude of the
CAP continuously monitored along the dorsal columns. Because the
dorsal columns in rat mainly receive their blood supply via the
vascular plexus in the adjacent gray matter, probably via the post-
capillary bed (Tveten,1976), and the arterial vessels that respond to
the constrictive effect of ET-1 are located in the graymatter (Tveten,
1976), the ET-1 injection here is intended to target the gray matter
adjacent to the dorsal columns. Vascular perfusion of the cord at
the injection site was continuously monitored using laser Doppler
ﬂowmetry (PeriFlux 3; Perimed, Sweden), and the severity of
ischemia was assessed as the maximal reduction of perfusion
expressed as a percentage of baseline. Because the dorsal vein
located on the dorsal columns obscures the access of the Doppler
probe for directly measuring the blood ﬂow in the dorsal columns,
the blood ﬂow at one side of the adjacent gray matter wasplitude of the CAP recovered to 93.9  3% of baseline (n ¼ 6) after the low frequency
l columns are shown in transverse sections in (E) 4.5 h after saline or ET-1 injection, in
ghout the dorsal columns, but the axons in the ventral portion of the dorsa columns are
n. DRG: dorsal root ganglia. REC: recording. DC: dorsal columns. Bars in E ¼ 10 mm.
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was gently placed on the surface of the cord and left in place
throughout the recording (i.e. no re-positioning for injection). At
the end of the electrical recordings the animals were either killed
by anesthetic over-dose, or perfused transcardially with glutaral-
dehyde (4% in 0.15 M phosphate buffer, pH 7.4) for later histological
processing.
KB-R7943 (30 mg/kg, n ¼ 6), SEA0400 (30 mg/kg, n ¼ 4), or
vehicle (40% dimethyl sulfoxide or DMSO in saline, n ¼ 8) were
slowly administered intra-arterially (i.a.) over 10 min via the can-
nulated right internal carotid artery, 60 min prior to the induction
of ischemia. KB-R7943 and SEA0400 were generous gifts from Eisai
Ltd, UK.
2.2. Recovery preparation
Rats (n ¼ 16) were anesthetized as described above and the
rectal temperature maintained at 36.5  0.5 C. The trachea was
intubated to allow monitoring of end-tidal carbon dioxide, and
artiﬁcial ventilation, if required, following ET-1 injection. Axonal
conduction along the dorsal columnswas assessed by recording the
CAP before any drug treatment (and prior to ET-1 injection), using
a similar protocol to that described above. ET-1 (2.28 nmol) was
injected bilaterally into the gray matter at the T13 vertebra using
the protocol described above (onset of injection: T0). This ﬁrst set of
ET-1 injections was followed 60 min (T60 min) later by a second set
of ET-1 injections (1.14 nmol) delivered w1 mm more caudally
(w550 mm lateral to midline, 1 ml injection at 200 mm and 600 mm
depths; 4  1 ml in total). The injection protocol was demonstrated
not to affect the function of the dorsal column axons by testing it
using the acute preparation described above. The animals were
allowed to recover from the anesthesia once spontaneous ventila-
tion was reliable, and checked twice a day for post-operative care
including manually emptying the bladder if urinary retention
occurred.
In order to determine the time course of the recovery of blood
ﬂow after ET-1 injection, laser Doppler ﬂowmetry was used
repeatedly to measure the blood ﬂow at the spinal injection site to
obtain the “absolute” values at T0, T10 min, T60 min, TDay1, and TDay3,
and all the values were normalized to the value at T0 for each
animal. Apart from keeping all the parameters of the Doppler
ﬂowmeter consistent for each measurement, the following
measures were also taken to minimize variability introduced by re-
positioning the Doppler probe: ﬁrst, the animal was anesthetized,
and the vertebrae were ﬁxed to isolate the spinal cord from
ventilatory movements and the arrangement was held stable for at
least half an hour before measurement; second, the probe was re-
positioned at precisely the same site of the cord, guided by char-
coal labeling and the pattern of pial blood vessels; third, large blood
vessels on the cord surface were avoided at the measurement site;
and fourth, for each measurement the maximal reading was noted
after ﬁne adjustments of the position of the probe on the cord. We
found that although re-positioning of the Doppler probe will
inevitably introduce variability of reading, the precautions above
provided an acceptable repeatability in naïve animals, when per-
formed by the same investigator. We therefore used this method to
estimate the recovery of blood ﬂow over 3 days.
For terminal examination, the rats were re-anesthetized (as
above) at day 3 post-treatment and conduction along the dorsal
column axons was assessed as before. The area under the CAP was
expressed as a percentage of that obtained prior to ET-1 injection.
The rats were then perfused transcardially with glutaraldehyde (4%
in 0.15 M phosphate buffer, pH 7.4).
For drug treatment, KB-R7943 (30 mg/kg, n ¼ 8) or vehicle (40%
DMSO in saline, n ¼ 8) were slowly administered intravenously(i.v.), 60 min before the injection of ET-1. To maintain blinding, the
drugs were coded by an independent investigator and the animals
were randomly assigned into each group. The electrophysiological
examinations were performed blind to the drug treatment
administered. The drug treatment was only revealed after all the
electrophysiological and histological data had been obtained and
analyzed.
2.3. Histology
A 2 cm length of the spinal cord containing the pre-labeled
injection site was cut transversely into blocks of 0.5 mm, which
were washed with 0.15 M phosphate buffer (15 min  3), and
treated with 1.5% buffered osmium tetroxide for 120 min. After
washing (10 min  3), the tissue blocks were dehydrated in a series
of alcohols with ascending concentrations (15 min in 30% alcohol,
15 min in 50% alcohol, 15 min in 90% alcohol, 3  20 min in 100%
alcohol). The tissues were placed in 100% propylene oxide for
30 min, followed by one repeat, then in 50% propylene oxide with
50% resin for 60 min, and in 25% propylene oxide with 75% resin for
another 60 min, and ﬁnally in 100% resin overnight at 4 C. The
resin was polymerized in an oven (60 C) for 24e36 h. The
embedded spinal cord blocks were cut transversely into 1 mm
sections and stained with toluidine blue (1%). Sections obtained
from each tissue block were ﬁrst examined grossly to identify the
block exhibiting the most severe dorsal column lesion for each
spinal cord. Here sections were selected for imaging and further
analysis. Analysis of the transverse, ‘two-dimensional’ lesion size,
instead of ‘three-dimensional’ lesion volume, was employed, based
on the assumption that only the transverse extent of the lesion
affects the number of conducting axons as all the axons run
longitudinally along the dorsal columns. In the recovery study, such
selected sections were used to quantify the area of the dorsal
column lesion expressed as a percentage of the whole dorsal
column area. The histological assessments were conducted blind.
Two samples in the KB-R7943 recovery trial were excluded from
histological analysis for technical reasons.
2.4. Statistics
Data were expressed as mean  SD. Student’s t test was used to
calculate the statistical signiﬁcance for single comparisons. ANOVA
was used for multiple comparisons, followed by Bonferroni post hoc
test. Spearman’s rank correlation test was used for correlation
analysis. P < 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Model of white matter ischemia: acute preparation
The electrophysiological studies assessed the primary afferent
axons in the dorsal column, as only the action potentials evoked in
these ﬁbers were recorded in the periphery (Fig. 1A). The magni-
tude of the evoked CAP along those ﬁbers indicates the number of
conducting axons (Cummins et al., 1979). Pilot experiments deter-
mined the optimal injection location (Fig. 1A & B) and the dose-
dependence of ET-1 (0e2.28 nmol) on the persisting terminal
electrophysiological deﬁcit. Electrically active axons, which
presumably have higher metabolic demand, were found to be more
vulnerable to the ischemia, as animals that had experienced
continuous stimulation at 50 Hz had signiﬁcantly reduced recovery
of the CAP compared with those that had experienced stimulation
at 1 Hz throughout the experiment (Supplementary Fig. 1). There-
fore, a period of 50 Hz stimulation (210 min) was applied to the
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(2.28 nmol) in acute experiments.
Vascular perfusion of the spinal cord remained stable during
stimulation at 1 Hz (Fig. 1C), but it increased promptly when the
stimulation frequency was increased to 50 Hz, before falling more
gradually toward a new steady level. The intraspinal injection of ET-
1 resulted in a profound reduction of perfusion to below 10% of
baseline withinw10 min, and it remained at this level forw60 min
before gradually increasing to achieve w20% of baseline 270 min
following ET-1 injection (when most acute experiments end).
Recovery ofw40% of baseline was achieved 450min following ET-1
injection (the longest time point recorded in some acute, terminal
experiments). In contrast, the control intraspinal injection of saline
had little effect on vascular perfusion (Fig. 1C).Fig. 2. Data showing the recovery model of ET-1-induced ischemia. The initial ischemia w
a second set of injections of 1.14 nmol administered 60 min after the initial set. A shows r
stimulation in the same animals at day 0 (pre-injection) and at day 3 post-injection, with s
injection CAP relative to that under the pre-injection CAP, following ET-1 (40.6  11%, n ¼ 6
conducted along the dorsal column axons. C shows transverse sections of the dorsal columns
tissue appears normal following saline injection, there is substantial degeneration of the d
surface. Stim: stimulus artifact. Data in B: mean  SD. ***P < 0.001, Student’s t test. Bars inRecordings of the CAP were stable during the period of stimu-
lation at 1 Hz (Fig. 1D). When the stimulation frequency was
increased to 50 Hz, the CAP diminished in amplitude by w10% to
reach a new plateau. In controls, saline injection, along with
continuous 50 Hz stimulation, further diminished the amplitude of
the CAP until the stimulation frequency was returned to 1 Hz at
t ¼ 180 min. The ﬁnal recovery of the amplitude of the CAP was
93.9  3% of baseline (n ¼ 6). Upon intraspinal injection of ET-1 the
CAP promptly reduced in amplitude such that it was completely
abolished within w10 min. Axonal conduction started to recover
w90 min later after a partial recovery in perfusion which usually
occurred approximately 60 min after ET-1 injection (Fig. 1C), sug-
gesting that local perfusion has to recover to a certain level (w20%
of baseline) before axonal conduction recovers. By the end of the
recording period, the amplitude of the CAP reached a stable level ofas induced by bilateral injections of 2.28 nmol ET-1 into the gray matter, followed by
epresentative, averaged compound action potentials (CAPs) evoked by supramaximal
aline or ET-1 treatment. B shows the averaged percentage of the area under the post-
) or saline injection (100.4  7%, n ¼ 5). ET-1 signiﬁcantly reduced the area of the CAP
(DC; outlined by arrowheads), 3 days after either saline or ET-1 injection. Whereas the
orsal column axons following ET-1 injection, except for a thin band beneath the pial
C ¼ 200 mm.
Fig. 3. Data showing the protection of axonal function by KB-R7943 and SEA0400 in
the acute experiment. A & B show representative CAPs obtained from animals injected
with ET-1 and treated with either vehicle (A) or KB-R7943 (B). The response attained at
the start of recording (solid line) indicates the maximal number of axons conducting in
response to the supramaximal electrical stimulus, but 30 min following ET-1 injection
no conducting axons could be detected (dashed line). In animals treated with KB-
R7943, the CAP obtained four hours after ET-1 injection was noticeably greater in
amplitude and area than that obtained from saline-treated controls (dotted line). Stim:
stimulus artifact. C shows similar ﬁndings, plotted against time, from all the animals
studied. The systemic administration of KB-R7943 or saline (arrow) had no immediate
detectable effect on the CAP, but there was a small reduction in the amplitude of the
CAP upon the onset of stimulation at 50 Hz, and a prompt reduction to zero upon the
injection of ET-1 (arrowhead). Conduction resumed at approximately the same time
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recovery was signiﬁcantly smaller than the recovery after saline
injection (P < 0.001). The amplitude of the CAP at the end of the
recording period (t ¼ 270 min) was not signiﬁcantly different from
the amplitude at t¼ 210min (paired Student’s t test) in either saline
or ET-1 group, suggesting that both recoveries had reached
a plateau by the end of the experiment. Histological examination of
the dorsal columns after ET-1 treatment (Fig. 1E) revealed signiﬁ-
cant pathology, especially of the myelinated axons in the ventral
portion of the dorsal columns. Compared with the normal
appearance of tightly-packed axons with intact myelin sheaths
found throughout the dorsal columns in the saline-treated animals,
many myelinated axons in animals injected with ET-1 appeared
swollen, in an oedematous region containing distended myelin
sheaths and expansion of the periaxonal space. The dorsal portion
of the dorsal columns was relatively intact after ET-1 injection.
The intraspinal injection of ET-1 reduced the mean systemic
arterial blood pressure by 0e50% (23  24%), but this always
returned to baseline within 150 min of ET-1 injection
(Supplementary Fig. 2). To ensure that the effects on axonal
conduction were not due to a direct ‘toxic’ effect of ET-1 on axons,
ET-1 was injected directly into the dorsal columns rather than into
the gray matter. No evidence of direct toxicity was detected
(Supplementary Fig. 3).3.2. Model of white matter ischemia: recovery preparation
The acute, terminal preparation allowed for continuous elec-
trophysiological monitoring of the axons as the ischemia developed
and evolved, but it was only feasible to study the ischemic axons for
a few hours following ischemia. To permit examination after
a longer period a recovery experiment was developed that allowed
the evolution of the ischemic lesion over days, or longer periods.
Since the local blood perfusion was estimated to recover to its full
extent by 1 day after ET-1 injection (Supplementary Fig. 4), the
animals were examined three days after ET-1 injection, in the belief
that the acute phase of any damage would have become fully
manifest at this time.
Indeed, examination of animals three days after intraspinal
injection revealed that ET-1-induced axonal injury persisted, as the
area under the CAP remained signiﬁcantly reduced (40.6  11% of
that before ET-1 injection, n¼ 6, Fig. 2A & B), whereas similar saline
control injection had little or no long term effect (100.4 7% of that
before saline injection, n ¼ 5, Fig. 2A & B). Histologically, the three
day period following the ischemic insult allowed the degenerating
axons to be easily distinguished such that there was a clear
difference between the infarcted and surviving regions of tissue
(Fig. 2C). The lower portion of the dorsal columns was most
severely affected, and in all cases the most superﬁcial tissue wasfollowing ET-1 (w100 min) irrespective of therapy, but in the animals treated with KB-
R7943 the recovery was signiﬁcantly greater, as represented graphically in E. D shows
changes in the relative perfusion of the spinal cord at the level of the lesion as
monitored continuously using laser Doppler ﬂowmetry. The administration (arrow) of
either KB-R7943 (KBR; 30 mg/kg, i.a.) or vehicle (Veh, i.a.) was associated with a brief
and mild reduction in perfusion, and the onset of 50 Hz stimulation caused a more
pronounced increase in perfusion. Perfusion was promptly reduced to less than 10%
upon the intraspinal injection of ET-1 (2.28 nmol) (t ¼ 0). E illustrates the signiﬁcant
improvement in recovery of axonal function achieved by treatment with KB-R7943 or
SEA0400, as judged by the amplitude of the conducted CAP (Veh 10.5  9% of baseline,
n ¼ 8; KBR 35.0  9% of baseline, n ¼ 6, P < 0.001; SEA 33.2  6% of baseline, n ¼ 4,
P < 0.001). F shows the minimal level of perfusion achieved with Veh (7.7  4% of
baseline, n ¼ 5), KBR (7.5  5% of baseline, n ¼ 4) or SEA (10.0  4% of baseline, n ¼ 4).
The severity of ischemia induced by ET-1 was not reduced by the drug treatments.
Data: mean  SD. ***P < 0.001, compared with vehicle, one-way ANOVA with Bon-
ferroni post hoc test.
Fig. 4. Data showing the protection of axonal function by KB-R7943 in the recovery
experiment. A shows representative, averaged (n ¼ 32) CAPs recorded from the same
animals before the induction of ischemia on day 0, and three days later, in response to
supramaximal electrical stimulation. Therapy with KB-R7943 (KBR, 30 mg/kg, i.v.)
administered 60 min prior to the initial ET-1 injection resulted in an increase in the
area under the CAP compared with vehicle (Veh, 40% DMSO in saline) when measured
after three days. B illustrates the area under the CAP at day 3 post-injection, expressed
as a percentage of the area at day 0 pre-injection, with KBR treatment (76.3  11%,
n ¼ 8) or Veh treatment (51.0  19%, n ¼ 8). Stim: stimulus artifact. Data: mean  SD.
**P < 0.01, Student’s t test.
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was a mixture of seemingly normal axons, and axons that were
undergoing demyelination or degeneration. Saline injection had
very little effect on the integrity of the dorsal columns (Fig. 2C).
3.3. Protection of axonal function: acute preparation
The administration of KB-R7943 (30 mg/kg, i.a.) sometimes
appeared transiently to reduce perfusion of the spinal cord
(Fig. 3D), but the drug had no discernable effect on the CAP prior to
the onset of ischemia, nor did the drug signiﬁcantly affect the
timing or magnitude of the loss of conduction upon ET-1 admin-
istration. However, notably, the drug signiﬁcantly improved the
recovery of the CAP following ischemia, in comparisonwith vehicle
treatment (35.0  9% of baseline for KB-R7943, n ¼ 6, vs. 10.5  9%
for vehicle, n¼ 8; P< 0.001; Fig. 3A, B, C & E). Importantly, the drug
had no signiﬁcant effect on the severity of ischemia following ET-1
(perfusion reduced to 7.5 5% of baseline for KB-R7943 vs. 7.74%
of baseline for vehicle; P > 0.05; Fig. 3D & F), showing that the
protective effect of KB-R7943 on axonal conduction was not due to
a diminution of the severity of ischemia.
In commonwith KB-R7943, treatment with SEA0400 (30mg/kg,
i.a.) also resulted in an increased recovery of the CAP (33.2  6% of
baseline, n ¼ 4) compared with vehicle treatment (10.5  9% of
baseline, n ¼ 8; P < 0.001; Fig. 3E). Again, the protection was
achieved without diminishing the severity of ischemia (Fig. 3F).
3.4. Protection of axonal function: recovery preparation
To determine whether the protection of axonal function
observed in the acute experiments represented a meaningful, i.e.
sustained, protection of function and structural integrity (rather
than, perhaps, a delay in degeneration), other experiments applied
electrophysiological and histological examinations to assess the
axons after a delay of three days following the ischemia. In these
experiments the severity of the lesion was increased by a second
intraspinal injection of ET-1 (equal to half the ﬁrst dose), rather
than the use of high frequency electrical stimulation. Treatment
with KB-R7943 (30 mg/kg, i.v.) signiﬁcantly increased the area
under the CAP (76.3  11% of baseline, n ¼ 8) at day 3 after ET-1
injection, compared with vehicle treatment (51.0  19% of base-
line, n ¼ 8; P < 0.01), as shown in Fig. 4.
In agreement with the electrophysiological ﬁndings, treatment
with KB-R7943 signiﬁcantly reduced the area of pathology in the
dorsal columns (55.6  15%, n ¼ 6) compared with vehicle treat-
ment (77.9 9%, n¼ 8; P< 0.01; Fig. 5AeC). There was a signiﬁcant
negative correlation between the lesion area and the area under the
CAP (P < 0.01, r ¼ 0.820, Spearman’s rank correlation test;
Fig. 5D).
4. Discussion
A novel in vivo model of transient focal ischemia has been
introduced and used to explore whether inhibition of the reverse-
mode operation of the NCX is effective in protecting the white
matter from ischemic degeneration. Both of the NCX inhibitors KB-
R7943 and SEA0400 were found signiﬁcantly to improve the
number of functional axons in the dorsal columns following
ischemia, as assessed by the magnitude of the conducted CAP
(increased byw200% above control in the acute experiments, and
byw50% in the recovery experiments). The axonal protection was
evident soon after the period of ischemia, and it persisted for at
least 3 days. Correspondingly, histological examination revealed
that the area of axonal degeneration in the dorsal columns was alsosigniﬁcantly reduced (by 29% 3 days after intraspinal injection) in
the treated animals.
4.1. Ischemia model
The new model comprises a lesion involving both the gray and
white matter, but the model may be especially valuable for
studying the white matter. For example the function of the affected
axons in the dorsal columns can be monitored electrophysiologi-
cally, serially over days, to assess the time course of axonal damage
and recovery, and the efﬁcacy of strategies for axonal protection.
This ability to assess axonal function serially is of particular interest,
since no such assessment of axonal function after ischemia has
been reported in vivo to our knowledge. The antidromic conduction
pathway described here, comprising the dorsal columns, spinal
roots, and peripheral nerves includes the site of the dorsal column
lesion (of course), but the cell bodies of the affected axons are
located remotely from the ET-1 injection site (within the dorsal root
ganglia) and so may be expected to be spared from direct ischemic
damage. This feature allows the effects of the ischemia on the axons
Fig. 5. Protection of axonal integrity by KB-R7943 in the recovery experiment. A and B show representative sections of the dorsal columns (outlined in solid line) at the site of
injection of ET-1 in animals treated with vehicle (Veh) or KB-R7943 (KBR), 3 days after injection. Regions with surviving axons appear dark (at this magniﬁcation), and degenerating
tissue appears pale. Sections were treated with osmium tetroxide and stained with 1% toluidine blue. C shows the area of the lesion expressed as a percentage of the area of the
whole dorsal columns: animals treated with KBR had signiﬁcantly smaller lesions in the dorsal columns (55.6  15%, n ¼ 6) than Veh-treated controls (77.9  9%, n ¼ 8, P < 0.01). D:
graph of the area of the lesion in the dorsal columns, expressed as a percentage of the area of the whole dorsal columns, vs. the area under the CAP, expressed as a percentage of the
area obtained prior to ET-1 injection (Spearman’s rank correlation test, P < 0.01, r ¼ 0.820). DC: dorsal columns. Bars in A&B ¼ 300 mm. Data in C: mean  SD. **P < 0.01, Student’s t
test. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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direct damage to the associated cell bodies. The protocol to induce
the lesion involves only minimal mechanical damage to the spinal
tissue, such that control animals show no electrophysiological
deﬁcits and only a few degenerating axons (sometimes apparent
along the injection track upon microscopic examination in high
resolution resin sections). In contrast to other, related studies (e.g.
Frost et al., 2006; Sozmen et al., 2009), the protocol adopted here
avoids the injection of ET-1 directly into the white matter, thereby
reducing the possibility of any ‘direct’ effect of ET-1 on glial cells or
axons. However, we have in fact found no direct effect of ET-1 on
axonal conduction upon direct injection of concentrated ET-1 into
the dorsal columns themselves. Indeed, we found that while ET-1
injection into the dorsal columns was inefﬁcient in inducing per-
sisting acute axonal injury, ET-1 injection into the gray matter
adjacent to the dorsal columns resulted in a profound reduction of
blood perfusion within the dorsal columns, causing ischemia and
the profound electrophysiological and structural damage.
A useful feature of the method is that the severity of the lesion
can be modulated in two ways, either by changing the frequency or
duration of electrical stimulation, or by repeating the injection of
ET-1 as vascular perfusion starts to return. The ﬁrst method is
especially useful as the insult is both convenient to administer, and
very easily graded.
The acute and recovery preparations are two integrated parts of
the model. The acute preparation allows for continuous monitoring
of the integrity of axonal function during the initial phase of
ischemia, including monitoring of physiological parameters such as
local vascular perfusion. This facility permits distinction between
whether a axonal protection is achieved by “direct” mechanisms
(i.e. by acting on axons) or by “indirect” mechanisms (e.g. byalleviating the ischemia) or both. The recovery preparation, clini-
cally more relevant, can be used to validate the acute ﬁndings by
determining whether any axonal protection is durable over days.
Histological examination of the lesioned tissue suggested the
presence of a gradient of vulnerability within the dorsal columns
along the dorso-ventral axis, with the ventral portion being most
severely affected. It seems likely that the more dorsal tissue
received some vascular-derived sustenance from the pial plexus
(Tveten, 1976), and even possibly from the cerebrospinal ﬂuid and
dorsal vein. If so, the new lesion may be helpful in modeling the
penumbra observed clinically in the white matter (Koga et al.,
2005; Murphy et al., 2008), and the efﬁcacy of different drugs in
neuroprotection can be revealed by how far ventrally in the dorsal
columns the border between surviving and degenerating tissue can
be extended.
4.2. Axonal protection
The NCX is a bi-directional transporter that plays an important
role in the regulation of the axoplasmic concentration of Ca2þ and
Naþ (Baker and McNaughton, 1976; Blaustein and Santiago, 1977).
The strategy of blocking the reverse-mode action of the NCX to
achieve axonal protection from ischemia was introduced in studies
by Stys, Waxman, Ransom and colleagues who removed oxygen, or
oxygen and glucose, from excised tissue studied in vitro (Stys et al.,
1992b; Ouardouz et al., 2005). The present model has permitted
examination of whether the therapeutic strategy is both feasible
and effective in a true ischemic lesion studied in vivo. The current
ﬁndings show that both KB-R7943 and SEA0400, selective inhibi-
tors of the reverse-mode action of the NCX, provide signiﬁcant
protection of axons from ischemic degeneration in vivo.
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Annunziato et al., 2004). Apart from inhibiting the NCX, it is also
reported to inhibit L-type calcium channels (Ouardouz et al., 2005),
NMDA receptors (Sobolevsky and Khodorov, 1999), the Naþ/Mg2þ
exchanger (Uetani et al., 2003), and nicotinic acetylcholine recep-
tors (Pintado et al., 2000). Indeed, the inhibition of the L-type Ca2þ
channel by KB-R7943 may contribute to the axonal protection
observed in this study as pharmacological inhibition of the L-type
Ca2þ channel has been shown to protect the optic nerve axons from
anoxic injury (Fern et al., 1995) by reducing the Ca2þ inﬂux through
the channel and/or by reducing the Ca2þ release from the internal
store (Ouardouz et al., 2003). However, the fact that the protective
effect of KB-R7943 is reproduced by another more speciﬁc inhibitor
of the reverse-mode action of the NCX, SEA0400 (Matsuda et al.,
2001), strengthens a belief that this shared property of the drugs
is important in their neuroprotective mode of action.
Pre-treatment with KB-R7943 provided robust protection of the
dorsal column axons, as assessed by both electrophysiological and
histological methods. A potential concern is that the protectionwas
misleadingly achieved by diminishing the severity of the ischemic
insult, but this possibility was discounted by the observation from
the laser Doppler ﬂowmetry that blood perfusion was not
improved by the drug, and in fact rather transiently reduced.
Another potential concern is that KB-R7943 might misleadingly
increase the amplitude of the CAP by some unsuspected mecha-
nism, giving the misleading impression of an increase in the
number of conducting axons, but this possibility was also dis-
counted by the observation that the same dose of KB-R7943 did not
change the waveform of the CAP in naïve animals (data not shown).
It is also theoretically possible that KB-R7943 achieved protection
by inducing hypothermia (Pignataro et al., 2004), as this state can
be neuroprotective (Stys et al., 1992a). However, in the acute
experiments the core temperature of the rats was maintained at
a stable level (36.5 0.5 C) throughout the experiment by external
heat, so hypothermia is unlikely to explain the axonal protection
observed in this study.We conclude that the ﬁndings obtained with
KB-R7943 administration are indeed due to protection of the axons
from the consequences of the ischemic insult.
In summary, a new model of white matter ischemia has been
developed in the adult rat spinal cord using vasoconstriction
induced by the intraspinal injection of ET-1. The model has been
used to demonstrate that two drugs that inhibit the reverse-mode
action of the NCX, KB-R7943 and SEA0400, are effective in pro-
tecting axons from ischemic injury in vivo, and that the protection
persists for at least 3 days.
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